GLP-1s Are Quietly Becoming the Most Versatile Drugs in Medicine

Four organ systems, a cancer signal, and a lifespan study in mice all point the same direction: this drug class outgrew its own category a long time ago.

Most people still think of GLP-1s as weight-loss drugs. That's fair, it's how they entered the cultural conversation. But that framing is starting to undersell what these drugs are actually turning out to do, and I think the more interesting story right now isn't the number on the scale. It's everything else showing up around it.

Start with what's already FDA-approved, not theoretical, not early-stage, approved. Semaglutide is cleared to reduce the risk of major cardiovascular events, heart attack, stroke, cardiovascular death, in adults with existing heart disease and obesity. What's striking about that finding is that the benefit didn't fully depend on how much weight a patient lost, which points to the drug doing something protective for the heart beyond simply making someone smaller. The same compound is approved to slow the progression of chronic kidney disease in adults who also have type 2 diabetes, its specific approved population, not chronic kidney disease broadly. Tirzepatide is approved to treat moderate to severe obstructive sleep apnea. And as of last year, semaglutide is approved for MASH, a serious liver condition that's been climbing fast alongside rates of obesity.

That's four separate organ systems, heart, kidney, lungs, liver, where a drug most people associate with appetite suppression is now doing formally recognized clinical work. That alone would make this one of the more versatile drug classes to come out of the last decade.

We keep calling these weight-loss drugs. At this point, that's like calling a smartphone a phone.

Then there's the research still building momentum. A 2026 study found GLP-1 use was associated with a 41 percent lower risk of developing obesity-related cancers in non-diabetic patients taking the drugs for weight loss, everything from breast and colorectal to kidney and pancreatic cancer. Separate research has linked GLP-1 use to a lower risk of cognitive decline, and early trial data on liraglutide, one of the older GLP-1 compounds, suggests it may slow shrinkage in parts of the brain tied to memory. Worth a caveat here: not every result in this space has landed the same way. A newer trial testing oral semaglutide directly in people already living with symptomatic Alzheimer's found this year that it did not slow their cognitive decline. The signal looks real in prevention. It hasn't yet translated into a treatment for people who already have the disease, and those are two different claims. There are also genuinely promising early signals around reduced cravings for alcohol and nicotine, likely tied to how these drugs interact with the brain's reward circuitry, an angle almost nobody was studying when these compounds first launched as diabetes treatments.

And now there's a newer thread worth watching too. A study published this month in Nature found that giving semaglutide to older female mice late in life extended their lifespan and improved muscle function, cognition, and markers of inflammation, in some ways going beyond what calorie restriction alone could do. It's an early, animal-only finding limited so far to female mice, and nobody's suggesting it translates directly to humans yet. But it fits the same pattern as everything else on this list: a drug developed for one narrow purpose keeps turning up benefits nobody fully anticipated.

I find that pattern more interesting than any single result. A cardiologist at Yale recently called these "generational breakthrough medications," and I think that's the right frame. Not because every promising early signal will hold up, some won't, that's how science works, but because the sheer range of systems these drugs appear to touch, metabolic, cardiovascular, renal, cognitive, is rare. Most drugs do one thing well. These seem to be doing several, and researchers are still working out why.

"The best kind of breakthrough is the one that keeps surprising the people who invented it."

— Paul Gravette, Founder & CEO, Gravette Capital